var data={"title":"Aminolevulinic acid (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Aminolevulinic acid (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/811785?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=aminolevulinic-acid-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Aminolevulinic acid (topical): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193009\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ameluz;</li>\n      <li>Levulan Kerastick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193010\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Levulan Kerastick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193012\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Photosensitizing Agent, Topical;</li>\n      <li>\n        Topical Skin Product</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193033\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Should only be applied by qualified medical personnel (not intended for application by patients).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinic keratoses:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel (Ameluz): Apply ~1 mm thick to actinic keratosis and to ~5 mm of surrounding skin; application area should not exceed 20 cm<sup>2</sup> and a maximum of 2 g at one time. Cover with an light-blocking occlusive dressing and leave on for 3 hours. After 3 hours of occlusion, remove dressing, wipe off remaining gel, and follow with red light illumination. Lesions that have not completely resolved after 3 months following the initial treatment may be retreated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution (Levulan Kerastick): Apply to actinic keratoses (<b>not</b> perilesional skin) followed 14 to 18 hours later by blue light illumination. Application/treatment may be repeated at a treatment site (once) after 8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinic cheilitis (off-label use):</b> Topical: Apply solution (20%) to lip lesion followed 2 to 3 hours later by photodynamic therapy. Application/treatment may be repeated as necessary once every 4 weeks or until complete clearing, for up to 3 treatment sessions (Alexiades-Armenakas 2004). Additional data may be necessary to further define the role of aminolevulinic acid in the treatment of this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193034\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193035\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193036\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193046\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ameluz: 10% (2 g) [contains isopropyl alcohol, phosphatidylcholine, soy, polysorbate 80, propylene glycol, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levulan Kerastick: 20% (1 ea) [contains alcohol, usp, isopropyl alcohol, laureth, polyethylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193011\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193038\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For topical use only; not for ophthalmic, oral, or intravaginal use. During light treatment, both patients and health care personnel should wear appropriate eye protection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Gel:</b> Carefully wipe all lesions with an ethanol or isopropanol-soaked cotton pad (to degrease skin) and remove any scaling or crusts prior to application. Gently roughen lesion surfaces (avoid bleeding). Using a gloved fingertip or a spatula, apply gel ~1 mm thick and include ~5 mm of surrounding skin. Application area should not exceed 20 cm<sup>2</sup> and no more than 2 g should be used at one time. May be applied to healthy skin around the lesion(s). Avoid mucous membranes (eyes, nostrils, mouth or ears); maintain a distance of 1 cm from these areas; rinse thoroughly if accidental contact with these areas occurs. Allow gel to dry ~10 minutes before covering with a light-blocking occlusive dressing. After 3 hours, remove dressing and wipe off residual gel. Immediately after removing dressing and residual gel, illuminate the treatment area with red light source. Position lamp 5 to 8 cm from patient&rsquo;s skin. Healthy untreated skin does not need protection during illumination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If unable to perform red light illumination within 3 hours of gel application, rinse off gel with saline and water. Protect lesion sites and surrounding skin from sunlight or prolonged intense light (eg, tanning beds, sun lamps) for 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Solution:</b> Clean and dry lesion prior to application. Dab lesion gently with wet applicator tip (apply enough to uniformly wet lesion without excess running or dripping). Only apply to affected skin. Do not apply to periorbital area, ocular tissue, or mucosal surfaces. Allow to dry, then reapply to same lesion. Apply to either scalp or facial lesions, but not to both simultaneously. Follow application with blue light exposure in 14 to 18 hours. Do not wash the application area during the time between application and photosensitization; after photosensitization, gently rinse actinic keratosis with water and pat dry. Stinging or burning may occur during blue light treatment. Following blue light treatment, the lesion will temporarily redden, swell and/or scale, which should resolve within 4 weeks after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If unable to perform the blue light treatment after topical application or if treatment with the blue light is interrupted or stopped, advise patient to avoid sunlight/bright light exposure to treated lesions (and wear a wide brimmed hat or other protective apparel) for at least 40 hours after application (burning/stinging sensation may still occur).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50192899\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Actinic keratoses:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gel (Ameluz): Lesion-directed and field-directed topical treatment of mild to moderate actinic keratosis of the face and scalp; to be used in conjunction with photodynamic therapy with narrowband red light illumination (using BF-RhodoLED lamp).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution (Levulan Kerastick): Topical treatment of minimally to moderately thick actinic keratoses of the face or scalp; to be used in conjunction with photodynamic therapy with blue light illumination (using BLU-U blue light).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193016\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Actinic cheilitis; Basal cell skin cancer, superficial, low risk; Squamous cell skin cancer in situ, low risk (Bowen disease)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193007\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aminolevulinic acid (topical) may be confused with aminolevulinic acid (systemic), methyl aminolevulinate</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193025\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (&le;35%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Severe burning skin (&le;50%; occurred during or shortly after illumination; most cases resolved in 1 to 4 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Burning sensation of skin (&le;92%), crusted skin (&le;71%), desquamation (&le;64% to 71%), stinging of the skin (severe: &le;50%), hyperpigmentation (&le;22% to 36%), hypopigmentation (&le;22% to 36%), exfoliation of skin (&le;19%), skin erosion (&le;14%), dermatological disease (5% to 12%), localized vesiculation (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site erythema (92% to 99%), local pain (&le;92%), application site irritation (72%), localized edema (35%), application site pruritus (14% to 34%), application site induration (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (9%), hyperalgesia (6%), local discomfort (3%), dysesthesia (&le;2%), chills, headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Urticaria (&le;2% to 7%), dermal ulcer (2% to 4%), pustules (1% to &le;4%), excoriation (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local inflammation (&le;7%), application site reaction (4%), application site discharge (&le;2%), localized tenderness (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eyelid edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Blurred vision, diplopia, eye irritation, fatigue, feeling hot, fever, local swelling, nervousness, ocular hyperemia, pain, petechia, photophobia, pruritus, pustular rash, skin blister, skin discoloration, temporary amnesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50192900\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to aminolevulinic acid or any component of the formulation; known allergy/hypersensitivity to porphyrins; known porphyria; hypersensitivity to soybean phosphatidylcholine (Ameluz); cutaneous photosensitivity at wavelengths of 400 to 450 nm (Levulan Kerastick); photodermatoses (Ameluz)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193023\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucous membrane irritation May cause irritation to mucous membranes; do not apply to mucous membranes; rinse with water if contact occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular injury: Eyelid edema has been observed with topical aminolevulinic acid. Do not apply into eyes; rinse with water if eye contact occurs. Illumination light therapy may result in eye irritation, glare, or injury. During light treatment, patients, health care personnel, and any others present during illumination should wear appropriate eye protection. Avoid staring directly into the light source. Eye exposure to red light must be prevented.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: Treatment site will become photosensitive following topical application. Patients should be instructed to avoid exposure to sunlight, bright indoor lights, or tanning beds during the period prior to blue light treatment or for 48 hours following application for red light treatment. Exposure may result in lesion burning, edema, erythema, and/or stinging. Sunscreen will not protect against visible light; head should be covered with light-opaque material or wide-brimmed hat. If unable to return the next day for blue light treatment, avoid sunlight/bright light exposure to treated lesions for at least 40 hours. If unable to perform red light illumination within 3 hours of gel application, protect lesion sites and surrounding skin from sunlight or prolonged intense light (eg, tanning beds, sun lamps) for 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin irritation: Excessive irritation may occur if solution (Levulan Kerastick) is applied under occlusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transient amnesia: Transient amnestic episodes have been reported with aminolevulinic acid in combination with photodynamic therapy (PTD). Advise patients to report amnesia that occurs after treatment.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coagulation defects: Has not been tested in individuals with coagulation defects (acquired or inherited). Avoid bleeding during lesion preparation in patients with coagulation defects; bleeding must be controlled prior to application.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitizing agents: Concomitant use of other known photosensitizing agents may increase the degree of photosensitivity reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For external use only. Do not apply to eyes or mucous membranes. Application of solution (Levulan Kerastick) should involve either scalp or face lesions, although not simultaneously; avoid application to perilesional skin. Should be applied by a qualified health professional.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50213630\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50213628\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=113610&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Photosensitizing Agents: May enhance the photosensitizing effect of Aminolevulinic Acid (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193020\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193021\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Systemic absorption following topical application of the gel is negligible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193022\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if aminolevulinic acid is present in breast milk. The manufacturer recommends that caution be exercised when administering aminolevulinic acid to breast-feeding women. Systemic absorption following topical application of the gel is negligible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193028\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Aminolevulinic acid is a metabolic precursor of the photosensitizer protoporphyrin IX (PpIX). Photosensitization following local/topical application of aminolevulinic acid occurs through the metabolic conversion to PpIX. When exposed to light of appropriate wavelength and energy, accumulated PpIX produces a photodynamic reaction resulting in local cytotoxicity. Precancerous and cancerous cells exhibit a higher rate of porphyrin induction compared to normal cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193029\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peak fluorescence intensity of protoporphyrin IX (PpIX): Actinic keratosis: Solution: 11 hours &plusmn; 1 hour; Perilesional skin: 12 hours &plusmn; 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Mean fluorescence clearance half-life of PpIX for lesions: Solution: 30 &plusmn; 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Gel: 3 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50193048\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Ameluz External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (2 g): $324.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Levulan Kerastick External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (1): $440.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50213639\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>ALA (CN);</li>\n      <li>Alacare (AT, AU, CH, CZ, DE, DK, FI, NZ, PL, PT, SE, SK);</li>\n      <li>Ameluz (AT, CZ, DE, EE, ES, GB, HR, HU, IE, IL, LT, LU, LV, MT, NL, NO, PL, SE, SI);</li>\n      <li>AmeLuz (DK);</li>\n      <li>Amneluz (PT);</li>\n      <li>Effala (FR);</li>\n      <li>Levulan Kerastick (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15552607\"></a>Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic cheilitis. <i>J Drugs Dermatol</i>. 2004;3(5):548-551.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/15552607/pubmed\" target=\"_blank\" id=\"15552607\">15552607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ameluz (aminolevulinic acid hydrochloride) [prescribing information]. Wakefield, MA: Biofrontera Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17190630\"></a>Braathen LR, Szeimies RM, Basset-Seguin N, et al; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. <i>J Am Acad Dermatol</i>. 2007;56(1):125-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/17190630/pubmed\" target=\"_blank\" id=\"17190630\">17190630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levulan Kerastick (aminolevulinic acid) [prescribing information]. Willmington, MA: DUSA Pharmaceuticals, Inc; March 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moloney FJ and Collins P, et al. Randomized, Double-Blind, Prospective Study to Compare Topical 5-Aminolaevulinic Acid Methylester With Topical 5-Aminolaevulinic Acid Photodynamic Therapy for Extensive Scalp Actinic Keratosis. <i>Br J Dermatol</i>. 2007;157(1):87-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/17501954/pubmed\" target=\"_blank\" id=\"17501954\">17501954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tierney E, Barker A, Ahdout J, et al. Photodynamic Therapy for the Treatment of Cutaneous Neoplasia, Inflammatory Disorders, and Photoaging. <i>Dermatol Surg</i>. 2009;35(5):725-746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/aminolevulinic-acid-topical-drug-information/abstract-text/19309338/pubmed\" target=\"_blank\" id=\"19309338\">19309338</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 113610 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50193009\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50193010\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50193012\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50193033\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50193034\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50193035\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50193036\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50193046\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50193011\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50193038\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50192899\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50193016\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50193007\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50193025\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50192900\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50193023\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50213630\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50213628\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F50193020\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50193021\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50193022\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50193028\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50193029\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50193048\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F50213639\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/113610|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=aminolevulinic-acid-topical-patient-drug-information\" class=\"drug drug_patient\">Aminolevulinic acid (topical): Patient drug information</a></li></ul></div></div>","javascript":null}